Catalyst Biosciences, Inc. (CBIO) Reaches $8.87 After 9.00% Up Move; TAIYO YUDEN LTD AMERICAN DEPOSITARY SHAR (TYOYY) Sellers Increased By 133.33% Their Shorts

Catalyst Biosciences, Inc. (NASDAQ:CBIO) Logo

TAIYO YUDEN LTD AMERICAN DEPOSITARY SHAR (OTCMKTS:TYOYY) had an increase of 133.33% in short interest. TYOYY’s SI was 700 shares in February as released by FINRA. Its up 133.33% from 300 shares previously. With 800 avg volume, 1 days are for TAIYO YUDEN LTD AMERICAN DEPOSITARY SHAR (OTCMKTS:TYOYY)’s short sellers to cover TYOYY’s short positions. It closed at $87.05 lastly. It is down 0.00% since February 13, 2018 and is . It has by 0.00% the S&P500.

The stock of Catalyst Biosciences, Inc. (NASDAQ:CBIO) is a huge mover today! The stock increased 6.62% or $0.55 during the last trading session, reaching $8.87. About 221,111 shares traded. Catalyst Biosciences, Inc. (NASDAQ:CBIO) has risen 44.06% since February 13, 2018 and is uptrending. It has outperformed by 44.06% the S&P500. Some Historical CBIO News: 15/05/2018 – Catalyst Biosciences Closes Above 50-Day Moving Average; 09/05/2018 – Catalyst Biosciences to Host Key Opinion Leader Meeting on Novel Treatments for Hemophilia B and Hemophilia with Inhibitors; 12/04/2018 – Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B; 15/05/2018 – Soros Management Buys New 3% Position in Catalyst Biosciences; 03/05/2018 – Catalyst Biosciences 1Q Loss/Shr 56c; 10/05/2018 – Catalyst Biosciences Announces Oral Presentation at the World Federation of Hemophilia 2018 World Congress; 23/03/2018 Catalyst Biosciences Access Event Scheduled By LifeSci Advisors; 12/04/2018 – Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial; 15/05/2018 – Ra Capital Management Buys 4.3% of Catalyst Biosciences; 15/05/2018 – Ghost Tree Capital Buys 3.8% Position in Catalyst BiosciencesThe move comes after 9 months positive chart setup for the $105.99 million company. It was reported on Feb, 13 by Barchart.com. We have $9.67 PT which if reached, will make NASDAQ:CBIO worth $9.54 million more.

Taiyo Yuden Co., Ltd. develops, manufactures, and sells electronic components worldwide. The company has market cap of $2.60 billion. It offers multilayer ceramic capacitors for use in smartphones, automobiles, and other devices; ferrite and applied products, such as inductors used in electronic equipment power and high-frequency circuits; integrated modules and devices, including film bulk acoustic resonator/surface acoustic wave devices for mobile communications and power supply modules; and other electronic components, such as energy devices used as backup power equipment for smart meters and other similar products, as well as peak current assistance for LED flashes. It has a 15.02 P/E ratio. The firm also provides noise suppression parts, such as bead inductors, common-mode choke coils, multilayer EMI suppression filters, and ring varistors; chip antennas; balun transformers; wireless modules; and aluminum electrolytic capacitors.

Another recent and important Taiyo Yuden Co., Ltd. (OTCMKTS:TYOYY) news was published by Seekingalpha.com which published an article titled: “IT Hardware: Key Takeaways From Our Recent Visits To Taiwan/Japan – Seeking Alpha” on December 19, 2017.

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. The company has market cap of $105.99 million. The Company’s product pipeline includes marzeptacog alfa, a Factor VIIa variant that completed a Phase I clinical trials evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A and B patients with inhibitors. It currently has negative earnings. The firm also develops CB 2679d/ISU304, a Factor IX drug, which has completed preclinical studies for the prophylactic treatment of individuals with hemophilia B; and CB 2782, a pre-clinical anti-C3 protease program for the treatment of dry age-related macular degeneration.

More notable recent Catalyst Biosciences, Inc. (NASDAQ:CBIO) news were published by: Globenewswire.com which released: “Catalyst Biosciences to Present at the Annual BIO CEO & Investor Conference – GlobeNewswire” on February 05, 2019, also Seekingalpha.com with their article: “Catalyst Bio’s MarzAA continues to show positive action in mid-stage hemophilia study – Seeking Alpha” published on February 08, 2019, Nasdaq.com published: “Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B – Nasdaq” on February 06, 2019. More interesting news about Catalyst Biosciences, Inc. (NASDAQ:CBIO) were released by: Streetinsider.com and their article: “Catalyst Biosciences (CBIO) Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for Treatment of Hemophilia B – StreetInsider.com” published on February 06, 2019 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Big Miss For Seattle Genetics (NASDAQ:SGEN); Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs – Benzinga” with publication date: February 08, 2019.

Catalyst Biosciences, Inc. (NASDAQ:CBIO) Ratings Chart